摘要
阿尔茨海默病(AD)是一种进行性发展的神经系统退行疾病,由于病因不明和发病隐匿,对于该疾病的诊疗和预后仍是我们当前迫切需要面对的挑战。因此,探究AD的发病机制显得日益重要。早期生长反应因子1(EGR1)是一种与细胞增殖、分化有关的核转录因子,参与人体内多个靶基因的表达调控。有研究发现,AD患者脑内的EGR1表达水平增高,且EGR1蛋白在神经元纤维缠结密度高的神经元中富集,提示EGR1与AD的发病或进展存在密切联系。该文主要从β淀粉样蛋白肽、异常磷酸化tau蛋白、胆碱能神经系统障碍、调控衰老程序以及细胞炎症等方面探讨EGR1与AD的病理关系,并对其参与AD发病机制的研究进展做一综述,旨在为未来AD的临床治疗及研究方向提供新思路。
Alzheimer’s disease(AD)is a progressive neurodegenerative disease.With unclear causes and gradual onset,its diagnosis,treatment,and prognosis remain a great challenge.Therefore,it is increasingly important to clarify the pathogenesis of AD.Early growth response factor 1(EGR1)is a nuclear transcription factor that is related to cell proliferation and differentiation and involved in regulating the expression of various target genes in humans.Studies have shown that EGR1 is significantly upregulated in the brain of patients with AD,and is enriched in neurons with a high density of neurofibrillary tangles,suggesting a close link between EGR1 and the development or progression of AD.This article reviews research progress on the role of EGR1 in the pathogenesis of AD from the aspects ofβamyloid peptide,abnormally phosphorylated tau protein,cholinergic system dysfunction,regulation of the aging process,and cell inflammation,aiming to provide new ideas for the clinical treatment and research of AD in the future.
作者
凌浩聪
巫昊洋
冯茂蕾
李扬
LING Hao-Cong;WU Hao-Yang;FENG Mao-Lei;LI Yang(Undergraduate,Clinical Medicine Major,The Second Clinical Medical College,Southern Medical University,Guangzhou,Guangdong 510282,China;Department of Geriatrics,Zhujiang Hospital,Southern Medical University,Guangzhou,Guangdong 510282,China)
出处
《国际神经病学神经外科学杂志》
2022年第3期97-101,共5页
Journal of International Neurology and Neurosurgery
基金
广东省自然科学基金(2018A0303130216)。
